Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Nolan Priedigkeit, M.D.


This page shows the publications Nolan Priedigkeit has written about Xenograft Model Antitumor Assays.
  1. Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets. J Natl Cancer Inst. 2019 04 01; 111(4):388-398.
    View in: PubMed
    Score: 0.027
  2. The CARMA3-Bcl10-MALT1 Signalosome Drives NF?B Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer. Cancer Res. 2018 03 01; 78(5):1225-1240.
    View in: PubMed
    Score: 0.024
  3. Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer. Clin Cancer Res. 2017 Mar 15; 23(6):1552-1563.
    View in: PubMed
    Score: 0.022
  4. Forkhead Box Q1 Is a Novel Target of Breast Cancer Stem Cell Inhibition by Diallyl Trisulfide. J Biol Chem. 2016 Jun 24; 291(26):13495-508.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.